Estrella Immunopharma Inc (ESLA)

ESLA....................https://stockcharts.com/sc3/ui/?s=ESLA&p=w&b=5&g=0&id=p86431144783

ESLA.............................................................https://stockcharts.com/sc3/ui/?s=ESLA&p=w&b=5&g=0&id=p86431144783

ESLA.......................................https://stockcharts.com/sc3/ui/?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA reports Monday 6/23

ESLA.....................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

Scanners will find this,mine did,it will only take 1 with 20k+ followers to promote this and with the current no manipulation(freely trading) it could jump up quickly

new bio pharma,trading freely,72%inside!10m float,45Xs buying ave.(serious loading,on 1st trial news)

Golden cross https://stockcharts.com/h-sc/ui?s=esla

Buys 2x the sells,nearly no dark trades https://ih.advfn.com/stock-market/NASDAQ/estrella-immunopharma-ESLA/trades

Nice chart,moving freely is rare!
In 10k@1.55

ESLA $16 12 month price target, news today - moving forward

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
4:46 PM ET 2/19/25 | BusinessWire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--February 19, 2025--

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC ("D. Boral Capital"), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00.

Valuation Highlights
-- D. Boral Capital's analysis focuses on the development of EB103 in B-cell
Non-Hodgkin's Lymphoma, emphasizing Estrella's ARTEMIS(R) T-cell
engineering platform that utilizes cellular mechanisms which closely
resemble those of endogenous T-cell receptors, producing a more natural
and regulated immune response.

-- The derived 12-month price target of $16.00 underscores market confidence
in Estrella's potential to capture significant market share in
immuno-oncology.

-- The models incorporate a 30% probability of success along with a 30%
discount rate, reflecting the early stage of Estrella's clinical
development.

ESLA, under $2

ESLA.......................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA..........................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA...................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA......................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA....................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA.........................................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783

ESLA.....................https://stockcharts.com/h-sc/ui?s=ESLA&p=W&b=5&g=0&id=p86431144783